|
|
| Line 1: |
Line 1: |
| {{drugbox |
| | #REDIRECT [[Sotalol]] |
| | IUPAC_name = ''N''-[4-(1-hydroxy-2-isopropylamino-<br>ethyl)-phenyl]-methanesulfonamide
| |
| | image = Sotalol.png
| |
| | CAS_number = 3930-20-9
| |
| | ATC_prefix=C07
| |
| | ATC_suffix=AA07
| |
| | PubChem=5253
| |
| | DrugBank=
| |
| | C=12 | H=20 | N=2 | O=3 | S=1
| |
| | molecular_weight = 272.3624 g/mol
| |
| | bioavailability = >95%
| |
| | metabolism = Not metabolised
| |
| | elimination_half-life = 12 hours
| |
| | excretion = [[Kidney|Renal]] <br> [[Mammary gland|Lactic]] (In lactating females)
| |
| | pregnancy_AU =
| |
| | pregnancy_US = B
| |
| | pregnancy_category =
| |
| | legal_status = Rx-only
| |
| | routes_of_administration = oral
| |
| }}
| |
| {{CMG}}
| |
| | |
| | |
| | |
| ==[[Sotalol (patient information)|For patient information, click here]]==
| |
| | |
| '''Sotalol''' (trade names '''Betapace''' and '''Betapace AF''', [[Berlex Laboratories]]) is a [[medication|drug]] used in individuals with rhythm disturbances ([[cardiac arrhythmia]]s) of the [[heart]], and to treat hypertension in some individuals.
| |
| | |
| ==Pharmacology==
| |
| It falls into the class III [[antiarrhythmic agents]] because it inhibits the inward [[potassium]] [[ion channel]]s in the heart. It is also a [[beta blocker]] because of its primary action on the β-[[adrenergic receptor]]s in the heart.
| |
| | |
| By blocking the potassium channels, sotalol prolongs [[repolarization]], therefore lengthening the [[QT interval]] and decreasing automaticity.
| |
| | |
| It also slows [[AV node|atrioventricular (AV) nodal]] conduction (beta-blocking effect).
| |
| | |
| Sotalol is a [[racemic]] mix of D and L [[enantiomers]]. The L isomer is a beta blocker.
| |
| | |
| Sotalol is not selected for its beta-blocking ability, but rather for its Class III (potassium blocking) properties.
| |
| | |
| ==Indications==
| |
| Sotalol is used to treat [[ventricular tachycardia]]s as well as [[atrial fibrillation]]. Betapace AF is specifically labeled for atrial fibrillation.
| |
| | |
| Some evidence suggests that sotalol should be avoided in the setting of decreased [[ejection fraction]] due to [[myocardial infarction|heart attack]].<!--
| |
| --><ref>{{cite journal | author = Waldo A, Camm A, deRuyter H, Friedman P, MacNeil D, Pauls J, Pitt B, Pratt C, Schwartz P, Veltri E | title = Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. | journal = Lancet | volume = 348 | issue = 9019 | pages = 7-12 | year = 1996 | id = PMID 8691967}}</ref>
| |
| | |
| ==Footnotes==
| |
| <references/>
| |
| | |
| ==See also==
| |
| *[[Antiarrhythmic agents]]
| |
| *[[Beta blocker]]
| |
| | |
| | |
| {{beta blockers}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Beta blockers]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| | |
| [[de:Sotalol]]
| |
| [[hr:Sotalol]]
| |
| [[hu:Szotalol]]
| |
| [[nl:Sotalol]]
| |
| [[pl:Sotalol]]
| |